
|Videos|June 4, 2021
Pipeline: Presbyopia treatment to finish Phase 3 late 2021
Orasis Pharmaceuticals drop in development for treating presbyopia
Advertisement
Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AOA 2026: The latest updates in keratoconus treatment advancements
2
AOA 2026: AREDS2 and AREDS2+B vitamin complex implications for AMD
3
Thea Pharma launches Zolymbus in the US as preservative-free bimatoprost gel
4
AOA 2026: Addressing contact lens challenges
5


























